Skip to main content
  • Clinical
      |Clinical
    • Acute Coronary Syndromes
    • Cardiac Surgery
    • Covid-19
    • Heart Failure
    • Heart Health
    • Heart Rhythm
    • Hypertension
    • Interventional Cardiology
    • Mitral Valve
    • Pharmaceutics
    • Structural Heart Disease
    • TAVR
    • Tricuspid Valve
    • Vascular & Endovascular
  • Management
      |Management
    • Chest Pain Guidelines
    • Compensation
    • Economics
    • Education & Training
    • Legal News
    • Patient Care
    • Policy & Regulations
    • Professional Associations
    • Quality
    • Revenue
    • Staffing
  • Technology
      |Technology
    • AI
    • Cardiac Imaging
    • Cath Lab
    • CT
    • CVIS
    • ECG
    • Echo
    • EP Lab
    • Informatics
    • MRI
    • Nuclear Cardiology
    • Remote Monitoring
  • Videos
  • Conferences
      |Conferences
    • ACC
    • AHA
    • ASE
    • ASNC
    • ESC
    • EuroPCR
    • HFSA
    • HRS
    • SCAI
    • SCCT
    • SIIM
    • SNMMI
    • STS
    • TCT
    • VIVA
  • Custom Content
      |Custom Content
    • Experience Stories
    • Webinars & Videos
  • Subscribe
  • Forty Under 40 Award
      |Forty Under 40 Award
    • Class of 2026
    • Class of 2025

Search form

Home

News Alert: CMS considers covering TAVR in asymptomatic patients

News You Need to Know Today
News Alert: CMS considers covering TAVR in asymptomatic patients
Tuesday, December 16, 2025
Link to Twitter Link to Facebook Link to Linkedin Link to Vimeo

News Alert

CMS considers Medicare coverage for TAVR in asymptomatic patients

After an official request from Edwards Lifesciences, CMS is rethinking its coverage policy for the use of TAVR to treat asymptomatic severe aortic stenosis. The agency is accepting public comments on this topic until Jan. 14. 

READ MORE >
Illustration of cardiologists going through the certification process. American College of Cardiology President B. Hadley Wilson, MD, discussed why the ACC and other leading cardiology groups are so eager to create a new, independent medical board. This has been a long-term goal for many years, he said, and now it may become a reality. 
Share on Twitter Share on Facebook Share on Linkedin

CMS considers Medicare coverage for TAVR in asymptomatic patients

Share on Twitter Share on Facebook Share on Linkedin
Illustration of cardiologists going through the certification process. American College of Cardiology President B. Hadley Wilson, MD, discussed why the ACC and other leading cardiology groups are so eager to create a new, independent medical board. This has been a long-term goal for many years, he said, and now it may become a reality. 
After an official request from Edwards Lifesciences, CMS is rethinking its coverage policy for the use of TAVR to treat asymptomatic severe aortic stenosis. The agency is accepting public comments on this topic until Jan. 14. 
READ MORE >

Innovate Healthcare thanks our partners for supporting our newsletters.
Sponsorship has no influence on editorial content.

Interested in reaching our audiences, contact our team

*|LIST:ADDRESSLINE|*

You received this email because you signed up for newsletters from Innovate Healthcare.
Change your preferences or unsubscribe here

Contact Us  |  Unsubscribe from all  |  Privacy Policy

© Innovate Healthcare, a TriMed Media brand
Innovate Healthcare

Recent Newsletters

Antiplatelet drug could be a breakthrough for treating heart attacks | FDA approves Abiomed's AI strategy
Rigid masking policy reduces COVID-19 cases among healthcare workers | MRI scans predict cardiac events
Cardiovascular Imaging: Echocardiograms & COVID-19 | SNMMI coverage | Cardiac CT exams & osteoporosis
Echocardiograms improve treatment for 1 in 3 COVID-19 patients | Plant-based diets boost cardiovascular health
Economics & Policy Update: Edwards, Abbott resolve patent dispute | Hypertension screening guidelines
Breast cancer 60% more fatal for heart attack survivors | Statin use among PAD patients | Edwards & Abbott end patent dispute
COVID-related strokes carry a greater risk of disability, death | $2.1B in the name of cardiovascular disease

Pagination

    • First page « First
    • Previous page ‹‹
    • Page …333
    • Page 334
    • Page 335
    • Page 336
    • Current page 337
    • Page 338
    • Page 339
    • Page 340
    • Page 341 …
    • Next page ››
    • Last page Last »
  • Home
  • News
  • Article Archive
  • Custom Content
  • Webinars
  • Press Releases
  • Content Studio
  • Advertising
  • Submit Press Release
  • Contact Us
  • Terms of Use
  • Privacy Policy
  • Cardiovascular Business
  • HealthExec
  • Radiology Business
 
© 2026 Innovate Healthcare | All Rights Reserved. | Terms of Use | Privacy Policy
 
Design by Adaptive Theme
Trimed Popup